Pharmaceutical company · CSLLY

CSL
clinical trial
pipeline

Registry checked

Published

Haematology is the largest mapped primary therapeutic group, with 5 of 19 active trials. This ranking covers mapped groups only. CSL222 (etranacogene dezaparvovec) is linked to 2 distinct active studies, with 2 Phase 3. CSL300 is linked to 2 distinct active studies, with 1 Phase 1, 1 Phase 3.

Phase 3 study NCT07094087 in Complex Cardiovascular Surgery With Cardiopulmonary Bypass lists estimated primary completion on 6 April 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

19active trials
as lead sponsor
  • Phase 11
  • Phase 25
  • Phase 36
  • Phase 42
  • Phase not recorded5

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

106 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

03Primary completion

Primary completion moved earlier by 33 days

2026-10-26 (estimated)2026-09-23 (actual)
26 Oct 202623 Sept 2026

Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

NCT06738485 · ClinicalTrials.gov
Recorded by ComplyRx
24 Oct 2026
Registry last updated
23 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130100011
2026-10-140000000
2026-10-150100011
2026-10-160000000
2026-10-171000011
2026-10-180000000
2026-10-190110131
2026-10-200000000
2026-10-210000000
2026-10-221000011
2026-10-230000000
2026-10-241110031
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals34201106 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

CSL222 (etranacogene dezaparvovec)

Canonical investigational asset

2
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Hemophilia B
Next primary completion
Not reported
Open drug

CSL300

Canonical investigational asset

2
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
End Stage Kidney Disease · End Stage Kidney Disease (ESKD)
Next primary completion
Not reported
Open drug

CE1226

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Alpha1 Antitrypsin Deficiency · Alpha1-Proteinase Inhibitor Deficiency · Emphysema
Next primary completion
Not reported
Open drug

IgPro10

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Next primary completion
Not reported
Open drug

BE1116

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Next primary completion
06 April 2027 · estimated
Open drug

CSL511 Fibrinogen Concentrate (Human)

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Acquired Fibrinogen Deficiency
Next primary completion
30 June 2027 · estimated
Open drug

14 of 19 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 14 of 19 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

CSL trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
BE1116

NCT07094087

Phase 3 · Recruiting

Trial source and qualifications

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

3 candidate observations · 1 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

  • pc date moved · Recorded 2026-08-18 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 15 Sept 2025 · actual
Primary completion: 06 Apr 2027 · estimated
Study completion: 05 May 2027 · estimated

2021202220232024202520262027202820292030
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
CSL511 Fibrinogen Concentrate (Human)

NCT06617897

Phase 3 · Recruiting

Trial source and qualifications

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

3 candidate observations · 1 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

  • pc date moved · Recorded 2026-10-13 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 01 Oct 2024 · actual
Primary completion: 30 Jun 2027 · estimated
Study completion: 30 Jun 2027 · estimated

2021202220232024202520262027202820292030
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Hemopexin (Human)

NCT06699849

Phase 2 · Recruiting

Trial source and qualifications

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 6 inspected observations were not displayed.

6 candidate observations · 0 shown · 0 recorded after primary completion · 6 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

6 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 10 Jul 2025 · actual
    Primary completion: 22 Oct 2027 · estimated
    Study completion: 22 Oct 2027 · estimated

    2021202220232024202520262027202820292030
    Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
    Vamifeport

    NCT07332091

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

    2 candidate observations · 2 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    Up to three verified eligible observations in the bounded history window.

    • pc date moved · Recorded 2026-09-17 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • status flip · Recorded 2026-10-22 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 22 Jan 2026 · actual
    Primary completion: 15 Apr 2028 · estimated
    Study completion: 15 May 2028 · estimated

    2021202220232024202520262027202820292030
    Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
    Anumigilimab

    NCT07224360

    Phase 2 · Recruiting

    Trial source and qualifications

    Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 02 Feb 2026 · actual
      Primary completion: 29 Jun 2028 · estimated
      Study completion: 29 Jun 2028 · estimated

      2021202220232024202520262027202820292030
      Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
      CSL222 (etranacogene dezaparvovec)

      NCT06003387

      Phase 3 · Recruiting

      Trial source and qualifications

      Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

      Duration ends at independently recorded study completion. Source date qualifications: end-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

      End clipped at the display horizon.

      0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      No eligible observations recorded in the inspected period.

        Start: 30 Jan 2024 · actual
        Primary completion: 04 Oct 2028 · estimated
        Study completion: 02 Apr 2032 · estimated

        2021202220232024202520262027202820292030

        Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

        6 selected of 10 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 0 actual primary completions, 0 untyped primary completions, 0 past estimates, 1 outside the horizon, 0 contradictory dates.

        04 / Therapeutic focus

        Where the activity is

        5

        active trials in Haematology

        Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

        Active trials by primary therapeutic area

        • Haematology5 trials
        • Renal & Urology3 trials
        • Respiratory2 trials
        • Cardiovascular1 trials
        • Neurology1 trials
        • Unmapped7 trials
        • Healthy volunteers0 trials

        Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

        06 / Related companies

        All companies

        No supported overlap was identified in the selected programme context. Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

        Sources, scope and methodology

        ClinicalTrials.gov lead-sponsor scope

        Enumerated controlled company group covers 234 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: CSL Limited · CSL Behring · Vifor Pharma, Inc.. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion. The additional bare Vifor Fresenius joint-venture identity is excluded pending exact controlled-entity evidence. Seqirus names already attributed to CSL Limited remain included.

        ClinicalTrials.gov

        Attribution coverage

        234 distinct registry candidates produced 234 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 149 unverified, 4 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

        Indexed enrichment

        210 scoped records have indexed enrichment and 24 do not. Missing enrichment does not remove a trial from cohort counts.

        Scope observation

        The successful attribution check completed at 2026-11-01T07:51:57.309Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 170646dd75cec2ff6ff80442b6736553099ebacc60dd747f85d15c8d0ba1326e.

        Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

        Dated canonical-attribution snapshot: 234 mapped lead-sponsored clinical studies across all statuses. 210 have indexed enrichment, 24 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

        Keep following
        what matters.

        Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

        Build your watch

        Choose what to track in the watch builder.